Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Homology Medicines Inc.
Headquarters: Bedford, MA, United States of America
Website: N/A
Year Founded: 2015
Status: Reverse-merged
BioCentury | Feb 25, 2025
Emerging Company Profile
Lifordi: Applying ADCs to autoimmune conditions
With $70M series A, biotech backed by Arch, 5am and Atlas is developing a targeted steroid it believes will be safer, with lower and less frequent dosing
BioCentury | Apr 18, 2024
Product Development
Rare disease spotlight: a leukodystrophy with small pipeline behind first approval
At least three MLD programs are coming up behind Orchard’s Lenmeldy, although three others were recently discontinued
BioCentury | Jan 17, 2024
Management Tracks
CEO departures at Aclaris and Vaxart
Plus: David Pyrce named CEO at Cognigenics, and updates from NextPoint, Hookipa, NeoImmuneTech, Neurogene, Paratek and Aspen
BioCentury | Dec 20, 2023
Data Byte
2023’s biotech reverse mergers
Half of the U.S.-listed biotechs that announced reverse mergers this year had been public for four years or less
BioCentury | Nov 16, 2023
Deals
Nov. 16 Quick Takes: Q32 takes merger route to NASDAQ via Homology deal
Plus: SpringWorks’ neurofibromatosis program headed for NDA and updates from Astellas, Propella, BMS, Merck, Nature’s Toolbox, Apollomics and Avistone
BioCentury | Jul 29, 2023
Deals
July 28 Quick Takes: AZ’s Alexion picks up Pfizer gene therapies
Plus: Homology exploring options and updates from Siga, BrainStorm
BioCentury | Mar 10, 2023
Management Tracks
Drachman leaving Neoleukin amid restructuring
Plus: Aspesi to lead HR at Editas and updates from Homology, GlycoMimetics and Ajax
BioCentury | Nov 23, 2022
Data Byte
Phenylketonuria pipeline breaks into new modalities
New approaches go beyond small molecules and enzymes to bacteria, mRNA, protein and gene therapies
BioCentury | Sep 27, 2022
Management Tracks
DEM names Grmusa CEO, Quéva CSO
Plus 5AM adds Arthur Tzianabos, June Lee as venture partners, and updates from Woebot, Flagship Biosciences and Radionetics
BioCentury | Sep 7, 2022
Management Tracks
Harpoon’s McMahon becomes CEO at Storm
Plus new CFO, CSO at Voyager and updates from Sonoma, Garuda, Alloy, Homology and more
Items per page:
1 - 10 of 58